drugset / Trial / NCT03919955

A Novel Pharmacological Therapy for Obstructive Sleep Apnea

NCT03919955

RandomizedCrossoverQuadruple-blindTreatment

Summary

A pharmacological, non-mechanical therapy for OSA that is efficacious and tolerable remains elusive. Here the investigators study the effect on sleep apnea severity of a combination of pharmacological agents (atomoxetine and oxybutynin, "AtoOxy") over a 1 month period of time. The current study will answer the following questions: Does ongoing, repeated-dose administration of atomoxetine-plus-oxybutynin (referred to as "AtoOxy") improve OSA severity, and do patients exhibit signs of symptomatic relief? Most importantly, which phenotypic subgroup of patients preferentially benefit from this intervention?

Timeline

Start
2019-09-03
Primary completion
2023-09-07
Completion
2023-09-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Atomoxetine Other / unclassified 80 mg Oral
Subject Oxybutynin Small molecule 5 mg Oral